Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine

Biochemical and Biophysical Research Communications

Volumn 324, Issue 2, 2004, Pages 773-781

  He, Yuxian ^a   Zhou, Yusen ^b   Liu, Shuwen ^a   Kou, Zhihua ^b   Li, Wenhui ^c   Farzan, Michael ^c   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c Brigham Women's Hosp   (United States)

Author keywords

Neutralizing antibody; Receptor binding domain; SARS CoV; Spike protein; Vaccine

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; NEUTRALIZING ANTIBODY; SPIKE PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG EFFECT; IMMUNIZATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RABBIT; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; MEMBRANE GLYCOPROTEINS; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECOMBINANT FUSION PROTEINS; VACCINES; VIRAL ENVELOPE PROTEINS;

CORONAVIRUS; ORYCTOLAGUS CUNICULUS;

EID: 5144234050     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.09.106     Document Type: Article

References (58)

1. T.G. Ksiazek, D. Erdman, C.S. Goldsmith, S.R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J.A. Comer, W. Lim, P.E. Rollin, S.F. Dowell, A.E. Ling, C.D. Humphrey, W.J. Shieh, J. Guarner, C.D. Paddock, P. Rota, B. Fields, J. DeRisi, J.Y. Yang, N. Cox, J.M. Hughes, J.W. LeDuc, W.J. Bellini, and L.J. Anderson A novel coronavirus associated with severe acute respiratory syndrome N. Engl. J. Med. 348 2003 1953 1966
2. C. Drosten, S. Gunther, W. Preiser, W.S. Van Der, H.R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R.A. Fouchier, A. Berger, A.M. Burguiere, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, J.C. Manuguerra, S. Muller, V. Rickerts, M. Sturmer, S. Vieth, H.D. Klenk, A.D. Osterhaus, H. Schmitz, and H.W. Doerr Identification of a novel coronavirus in patients with severe acute respiratory syndrome N. Engl. J. Med. 348 2003 1967 1976
3. J.S. Peiris, S.T. Lai, L.L. Poon, Y. Guan, L.Y. Yam, W. Lim, J. Nicholls, W.K. Yee, W.W. Yan, M.T. Cheung, V.C. Cheng, K.H. Chan, D.N. Tsang, R.W. Yung, T.K. Ng, and K.Y. Yuen Coronavirus as a possible cause of severe acute respiratory syndrome Lancet 361 2003 1319 1325
4. M.A. Marra, S.J.M. Jones, C.R. Astell, R.A. Holt, A. Brooks-Wilson, Y.S.N. Butterfield, J. Khattra, J.K. Asano, S.A. Barber, S.Y. Chan, A. Cloutier, S.M. Coughlin, D. Freeman, N. Girn, O.L. Griffith, S.R. Leach, M. Mayo, H. McDonald, S.B. Montgomery, P.K. Pandoh, A.S. Petrescu, A.G. Robertson, J.E. Schein, A. Siddiqui, D.E. Smailus, J.M. Stott, G.S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T.F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G.A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R.C. Brunham, M. Krajden, M. Petric, D.M. Skowronski, C. Upton, and R.L. Roper The genome sequence of the SARS-associated coronavirus Science 300 2003 1399 1404
5. P.A. Rota, M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, J.P. Icenogle, S. Penaranda, B. Bankamp, K. Maher, M.H. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J.L. DeRisi, Q. Chen, D. Wang, D.D. Erdman, T.C.T. Peret, C. Burns, T.G. Ksiazek, P.E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Gunther, A.D.M.E. Osterhaus, C. Drosten, M.A. Pallansch, L.J. Anderson, and W.J. Bellini Characterization of a novel coronavirus associated with severe acute respiratory syndrome Science 300 2003 1394 1399
6. Chinese SARS Molecular Epidemiology Consortium, Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China, Science 303 (2004) 1666-1669
7. K.V. Holmes, and L. Enjuanes VIROLOGY: the SARS coronavirus: a postgenomic era Science 300 2003 1377 1378
8. Y. Guan, B.J. Zheng, Y.Q. He, X.L. Liu, Z.X. Zhuang, C.L. Cheung, S.W. Luo, P.H. Li, L.J. Zhang, Y.J. Guan, K.M. Butt, K.L. Wong, K.W. Chan, W. Lim, K.F. Shortridge, K.Y. Yuen, J.S.M. Peiris, and L.L.M. Poon Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China Science 302 2003 276 278
9. F. Fleck SARS virus returns to China as scientists race to find effective vaccine Bull. World Health Organ. 82 2004 152 153
10. E. Marshall, and M. Enserink Medicine. Caution urged on SARS vaccines Science 303 2004 944 946
11. Y. Oba The use of corticosteroids in SARS N. Engl. J. Med. 348 2003 2034 2035
12. H. Wang, Y. Ding, X. Li, L. Yang, W. Zhang, and W. Kang Fatal aspergillosis in a patient with SARS who was treated with corticosteroids N. Engl. J. Med. 349 2003 507 508
13. M. Enserink One year after outbreak, SARS virus yields some secrets Science 304 2004 1097
14. D. Cavanagh S.G. Siddell The Coronaviridae 1995 Plenum Press New York and London 73 114
15. M.M. Lai, and D. Cavanagh The molecular biology of coronaviruses Adv. Virus Res. 48 1997 1 100
16. T.M. Gallagher, and M.J. Buchmeier Coronavirus spike proteins in viral entry and pathogenesis Virology 279 2001 371 374
17. J.J. Phillips, M.M. Chua, G.F. Rall, and S.R. Weiss Murine coronavirus spike glycoprotein mediates degree of viral spread, inflammation, and virus-induced immunopathology in the central nervous system Virology 301 2002 109 120
18. K.V. Holmes SARS-associated coronavirus N. Engl. J. Med. 348 2003 1948 1951
19. T.Y. Ho, S.L. Wu, S.E. Cheng, Y.C. Wei, S.P. Huang, and C.Y. Hsiang Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein Biochem. Biophys. Res. Commun. 313 2004 938 947
20. W.H. Li, M.J. Moore, N.Y. Vasilieva, J.H. Sui, S.K. Wong, A.M. Berne, M. Somasundaran, J.L. Sullivan, K. Luzuriaga, T.C. Greenough, H.Y. Choe, and M. Farzan Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Nature 426 2003 450 454
21. P. Prabakaran, X. Xiao, and D.S. Dimitrov A model of the ACE2 structure and function as a SARS-CoV receptor Biochem. Biophys. Res. Commun. 314 2004 235 241
22. D.S. Dimitrov The secret life of ACE2 as a receptor for the SARS virus Cell 115 2003 652 653
23. P. Wang, J. Chen, A. Zheng, Y. Nie, X. Shi, W. Wang, G. Wang, M. Luo, H. Liu, L. Tan, X. Song, Z. Wang, X. Yin, X. Qu, X. Wang, T. Qing, M. Ding, and H. Deng Expression cloning of functional receptor used by SARS coronavirus Biochem. Biophys. Res. Commun. 315 2004 439 444
24. S.K. Wong, W. Li, M.J. Moore, H. Choe, and M. Farzan A 193-amino-acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2, J. Biol. Chem. 279 2003 3197 3201
25. X. Xiao, S. Chakraborti, A.S. Dimitrov, K. Gramatikoff, and D.S. Dimitrov The SARS-CoV S glycoprotein: expression and functional characterization Biochem. Biophys. Res. Commun. 312 2003 1159 1164
26. G.J. Babcock, D.J. Esshaki, W.D. Thomas Jr., and D.M. Ambrosino Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor J. Virol. 78 2004 4552 4560
27. S. Jiang, K. Lin, N. Strick, and A.R. Neurath HIV-1 inhibition by a peptide Nature 365 1993 113
28. C.T. Wild, D.C. Shugars, T.K. Greenwell, C.B. McDanal, and T.J. Matthews Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection Proc. Natl. Acad. Sci. USA 91 1994 9770 9774
29. S. Liu, G. Xiao, Y. Chen, Y. He, J. Niu, C. Escalante, H. Xiong, J. Farmar, A.K. Debnath, P. Tien, and S. Jiang Interaction between the heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implication for virus fusogenic mechanism and identification of fusion inhibitors Lancet 363 2004 938 947
30. B. Tripet, M.W. Howard, M. Jobling, R.K. Holmes, K.V. Holmes, and R.S. Hodges Structural characterization of the SARS-coronavirus spike S fusion protein core J. Biol. Chem. 279 2004 20836 20849
31. D.C. Chan, D. Fass, J.M. Berger, and P.S. Kim Core structure of gp41 from the HIV envelope glycoprotein Cell 89 1997 263 273
32. B.J. Bosch, Z.R. van der, C.A. de Haan, and P.J. Rottier The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex J. Virol. 77 2003 8801 8811
33. Y. Xu, Y. Liu, Z. Lou, L. Qin, X. Li, Z. Bai, H. Pang, P. Tien, G.F. Gao, Z. Rao, Structural basis for coronavirus-mediated membrane fusion: crystal structure of MHV spike protein fusion core, J. Biol. Chem. Apr. 27 [Epub ahead of print] (2004)
34. Z.Y. Yang, W.P. Kong, Y. Huang, A. Roberts, B.R. Murphy, K. Subbarao, and G.J. Nabel A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice Nature 428 2004 561 564
35. H. Bisht, A. Roberts, L. Vogel, A. Bukreyev, P.L. Collins, B.R. Murphy, K. Subbarao, and B. Moss Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice Proc. Natl. Acad. Sci. USA 101 2004 6641 6646
36. A. Bukreyev, E.W. Lamirande, U.J. Buchholz, L.N. Vogel, W.R. Elkins, M. St Claire, B.R. Murphy, K. Subbarao, and P.L. Collins Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS Lancet 363 2004 2122 2127
37. H. Vennema, R.J. de Groot, D.A. Harbour, M. Dalderup, T. Gruffydd-Jones, M.C. Horzinek, and W.J. Spaan Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization J. Virol. 64 1990 1407 1409
38. W.V. Corapi, C.W. Olsen, and F.W. Scott Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus J. Virol. 66 1992 6695 6705
39. S. Jiang, K. Lin, and A.R. Neurath Enhancement of human immunodeficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41 J. Exp. Med. 174 1991 1557 1563
40. L.J. Reed, and H. Muench A simple method of estimating fifty per cent endpoints Am. J. Hyg. 27 1938 493 497
41. S.K. Wong, W. Li, M.J. Moore, H. Choe, and M. Farzan A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2 J. Biol. Chem. 279 2004 3197 3201
42. H. Zhang, G. Wang, J. Li, Y. Nie, X. Shi, G. Lian, W. Wang, X. Yin, Y. Zhao, X. Qu, M. Ding, and H. Deng Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies J. Virol. 78 2004 6938 6945
43. Y. Nie, G. Wang, X. Shi, H. Zhang, Y. Qiu, Z. He, W. Wang, G. Lian, X. Yin, L. Du, L. Ren, J. Wang, X. He, T. Li, H. Deng, and M. Ding Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection J. Infect. Dis. 190 2004 1119 1126
44. B.J. Zheng, K.H. Wong, J. Zhou, K.L. Wong, B.W. Young, L.W. Lu, and S.S. Lee SARS-related virus predating SARS outbreak, Hong Kong Emerg. Infect. Dis. 10 2004 176 178
45. K. Subbarao, J. McAuliffe, L. Vogel, G. Fahle, S. Fischer, K. Tatti, M. Packard, W.J. Shieh, S. Zaki, and B. Murphy Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice J. Virol. 78 2004 3572 3577
46. J. ter Meulen, A.B. Bakker, E.N. van den Brink, G.J. Weverling, B.E. Martina, B.L. Haagmans, T. Kuiken, J. de Kruif, W. Preiser, W. Spaan, H.R. Gelderblom, J. Goudsmit, and A.D. Osterhaus Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets Lancet 363 2004 2139 2141
47. J. Sui, W. Li, A. Murakami, A. Tamin, L.J. Matthews, S.K. Wong, M.J. Moore, A.S. Tallarico, M. Olurinde, H. Choe, L.J. Anderson, W.J. Bellini, M. Farzan, and W.A. Marasco Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association Proc. Natl. Acad. Sci. USA 101 2004 2536 2541
48. H. Kubo, Y.K. Yamada, and F. Taguchi Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein J. Virol. 68 1994 5403 5410
49. M. Godet, J. Grosclaude, B. Delmas, and H. Laude Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein J. Virol. 68 1994 8008 8016
50. A. Bonavia, B.D. Zelus, D.E. Wentworth, P.J. Talbot, and K.V. Holmes Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E J. Virol. 77 2003 2530 2538
51. R.K. Williams, G.S. Jiang, and K.V. Holmes Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins Proc. Natl. Acad. Sci. USA 88 1991 5533 5536
52. A.L. Smith, C.B. Cardellichio, D.F. Winograd, M.S. de Souza, S.W. Barthold, and K.V. Holmes Monoclonal antibody to the receptor for murine coronavirus MHV-A59 inhibits viral replication in vivo J. Infect. Dis. 163 1991 879 882
53. T.W. Geisbert, L.E. Hensley, J.B. Geisbert, and P.B. Jahrling Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections Virology 293 2002 15 19
54. A. Takada, and Y. Kawaoka Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications Rev. Med. Virol. 13 2003 387 398
55. A. Takada, S. Watanabe, K. Okazaki, H. Kida, and Y. Kawaoka Infectivity-enhancing antibodies to Ebola virus glycoprotein J. Virol. 75 2001 2324 2330
56. C.W. Olsen, W.V. Corapi, R.H. Jacobson, R.A. Simkins, L.J. Saif, and F.W. Scott Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity J. Gen. Virol. 74 Pt. 4 1993 745 749
57. P. Roben, J.P. Moore, M. Thali, J. Sodroski, C.F. Barbas III, and D.R. Burton Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 J. Virol. 68 1994 4821 4828
58. J.A. Kessler, P.M. McKenna, E.A. Emini, C.P. Chan, M.D. Patel, S.K. Gupta, G.E. Mark III, C.F. Barbas III, D.R. Burton, and A.J. Conley Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates AIDS Res. Hum. Retroviruses 13 1997 575 582